Half of the aggressive ovarian cancer subtype, high-grade serous cancer (HGSC), have abnormalities in DNA repair and should be susceptible to new PARP inhibitor therapy, yet not all those respond.
Team members: Dr Cassandra Vandenberg, Dr Mattew Wakefield
By developing new models of studying human ovarian cancers in the laboratory (patient-derived xenografts, PDX, which have abnormal DNA repair), we are exploring which markers predict which ovarian cancers will respond best to these exciting new treatments and most importantly, how to prevent resistance to PARP inhibitors in some of these cancers.